OPIPZA (aripiprazole) by Otsuka is indications, is unclear. First approved in 2024.
Drug data last refreshed 2h ago · AI intelligence enriched 2d ago
OPIPZA is an oral film formulation of aripiprazole, an atypical antipsychotic approved by the FDA on July 22, 2024. The drug works through partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors, combined with antagonist activity at 5-HT2A receptors. The specific indications for this formulation have not been disclosed in available data.
Early-stage product with significant runway; brand team is likely small but expanding as market penetration begins.
indications, is unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
Atypical Antipsychotic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole
Worked on OPIPZA at Otsuka? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on OPIPZA offers entry into the high-demand psychiatric pharmaceutical space with a newly approved formulation differentiation. The 15-year LOE runway provides stable, long-term career growth opportunities in brand building and market penetration.